Massmutual Trust Co. FSB ADV Has $23.20 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Massmutual Trust Co. FSB ADV boosted its position in Johnson & Johnson (NYSE:JNJ) by 2.0% in the 2nd quarter, Holdings Channel reports. The firm owned 166,598 shares of the company’s stock after buying an additional 3,230 shares during the quarter. Johnson & Johnson accounts for approximately 1.6% of Massmutual Trust Co. FSB ADV’s portfolio, making the stock its 10th biggest position. Massmutual Trust Co. FSB ADV’s holdings in Johnson & Johnson were worth $23,204,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Thoroughbred Financial Services LLC increased its position in shares of Johnson & Johnson by 14,147.0% during the second quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock worth $401,425,000 after acquiring an additional 3,986,071 shares during the period. Renaissance Technologies LLC increased its position in shares of Johnson & Johnson by 145.5% during the second quarter. Renaissance Technologies LLC now owns 4,341,162 shares of the company’s stock worth $604,637,000 after acquiring an additional 2,572,695 shares during the period. APG Asset Management N.V. increased its position in shares of Johnson & Johnson by 61.4% during the second quarter. APG Asset Management N.V. now owns 5,188,736 shares of the company’s stock worth $634,604,000 after acquiring an additional 1,973,700 shares during the period. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 0.7% during the second quarter. Vanguard Group Inc. now owns 225,158,988 shares of the company’s stock worth $31,360,143,000 after acquiring an additional 1,627,370 shares during the period. Finally, Nordea Investment Management AB increased its position in shares of Johnson & Johnson by 14.2% during the first quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock worth $1,217,494,000 after acquiring an additional 1,079,751 shares during the period. 72.01% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have recently commented on JNJ. Credit Suisse Group set a $156.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Raymond James reduced their target price on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 17th. Barclays began coverage on shares of Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 target price on the stock. Bank of America reaffirmed a “hold” rating and set a $150.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $150.60.

JNJ stock traded down $0.01 during trading on Thursday, hitting $130.40. 2,681,736 shares of the company’s stock traded hands, compared to its average volume of 7,507,391. The firm has a market capitalization of $341.88 billion, a P/E ratio of 15.94, a PEG ratio of 2.19 and a beta of 0.68. The business has a fifty day simple moving average of $130.05 and a two-hundred day simple moving average of $135.78. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.16. The company had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. Johnson & Johnson’s revenue was down 1.3% compared to the same quarter last year. During the same period last year, the company posted $2.10 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 2.91%. The ex-dividend date was Monday, August 26th. Johnson & Johnson’s payout ratio is 46.45%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Do You Need a Fiduciary?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.